StatFinn – EPID Research: Strong and profitable growth continued in 2017
(Espoo, Finland, 19.4.2018) Contract research organization StatFinn – EPID Research reports record growth in 2017. The financial statement shows total sales of € 7,2 million (2016: 4,7 million) with a growth rate of 53,7 percent (49,2). Earnings before taxes grew to € 1,1 million (0,7).
“I am extremely pleased with our achievements in 2017. During the year, we merged StatFinn and EPID Research, while at the same time once again reached a record growth in sales and earnings. The continued trust from our clients for our services in clinical trials, Real-World Evidence and hybrid studies is a testimony to our client-oriented scientific and methodological expertise,” says Eero Mertano, CEO of StatFinn – EPID Research.
“I wish to express my strong gratitude to our personnel, whose commitment and positive attitude made this success possible. Based on our broad client-base and growing team of experts, we expect our strong global growth to continue in 2018.”
For additional information:
Eero Mertano, CEO, email@example.com, +358 40 769 6275
StatFinn and EPID present strong growth in 2016
StatFinn and EPID Research join forces in clinical data analytics and Real-World Evidence
(Espoo, Finland, 16.1.2017) StatFinn and EPID Research have decided to merge their operations in order to offer a full range of services to their clients in clinical data analytics and Real-World Evidence from Phase I to Phase IV and beyond. The combined company employs over 70 experts with presence in five countries: Estonia, Finland, Poland, Sweden and Switzerland. The new combination will carry on using both brands StatFinn and EPID Research.